Cargando…

First Live-Experience Session with PET/CT Specimen Imager: A Pilot Analysis in Prostate Cancer and Neuroendocrine Tumor

Objective: to evaluate the feasibility of the intra-operative application of a specimen PET/CT imager in a clinical setting. Materials and methods: this is a pilot analysis performed in three patients who received an intra-operative administration of (68)Ga-PSMA-11 (n = 2) and (68)Ga-DOTA-TOC (n = 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Muraglia, Lorenzo, Mattana, Francesco, Travaini, Laura Lavinia, Musi, Gennaro, Bertani, Emilio, Renne, Giuseppe, Pisa, Eleonora, Ferrari, Mahila Esmeralda, Fumagalli Romario, Uberto, De Cobelli, Ottavio, Fusco, Nicola, Ceci, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953571/
https://www.ncbi.nlm.nih.gov/pubmed/36831181
http://dx.doi.org/10.3390/biomedicines11020645
_version_ 1784893910801186816
author Muraglia, Lorenzo
Mattana, Francesco
Travaini, Laura Lavinia
Musi, Gennaro
Bertani, Emilio
Renne, Giuseppe
Pisa, Eleonora
Ferrari, Mahila Esmeralda
Fumagalli Romario, Uberto
De Cobelli, Ottavio
Fusco, Nicola
Ceci, Francesco
author_facet Muraglia, Lorenzo
Mattana, Francesco
Travaini, Laura Lavinia
Musi, Gennaro
Bertani, Emilio
Renne, Giuseppe
Pisa, Eleonora
Ferrari, Mahila Esmeralda
Fumagalli Romario, Uberto
De Cobelli, Ottavio
Fusco, Nicola
Ceci, Francesco
author_sort Muraglia, Lorenzo
collection PubMed
description Objective: to evaluate the feasibility of the intra-operative application of a specimen PET/CT imager in a clinical setting. Materials and methods: this is a pilot analysis performed in three patients who received an intra-operative administration of (68)Ga-PSMA-11 (n = 2) and (68)Ga-DOTA-TOC (n = 1), respectively. Patients were administrated with PET radiopharmaceuticals to perform radio-guided surgery with a beta-probe detector during radical prostatectomy for prostate cancer (PCa) and salvage lymphadenectomy for recurrent neuroendocrine tumor (NET) of the ileum, respectively. All procedures have been performed within two ongoing clinical trials in our Institute (NCT05596851 and NCT05448157). Pathologic assessment with immunohistochemistry (PSMA-staining and SSA immunoreactivity) was considered as standard of truth. Specimen images were compared with baseline PET/CT images and histopathological analysis. Results: Patients received 1 MBq/Kg of (68)Ga-PSMA-11 (PCa) or 1.2 MBq/Kg of (68)Ga-DOTA-TOC (NET) prior to surgery. Specimens were collected, positioned in the dedicated specimen container, and scanned to obtain high-resolution PET/CT images. In all cases, a perfect match was observed between the findings detected by the specimen imager and histopathology. Overall, the PET spatial resolution was sensibly higher for the specimen images compared to the baseline whole-body PET/CT images. Furthermore, the use of the PET/CT specimen imager did not significantly interfere with any procedures, and the overall length of the surgery was not affected using the PET/CT specimen imager. Finally, the radiation exposure of the operating theater staff was lower than 40 µSv per procedure (range 26–40 μSv). Conclusions: the image acquisition of specimens obtained by patients who received intra-surgery injections of (68)Ga-PSMA-11 and (68)Ga-DOTA-TOC was feasible and reliable also in a live-experience session and has been easily adapted to surgery daily practice. The high sensitivity, together with the evaluation of intra-lesion tumor heterogeneity, were the most relevant results since the data derived from specimen PET/CT imaging matched perfectly with the histopathological analysis.
format Online
Article
Text
id pubmed-9953571
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99535712023-02-25 First Live-Experience Session with PET/CT Specimen Imager: A Pilot Analysis in Prostate Cancer and Neuroendocrine Tumor Muraglia, Lorenzo Mattana, Francesco Travaini, Laura Lavinia Musi, Gennaro Bertani, Emilio Renne, Giuseppe Pisa, Eleonora Ferrari, Mahila Esmeralda Fumagalli Romario, Uberto De Cobelli, Ottavio Fusco, Nicola Ceci, Francesco Biomedicines Article Objective: to evaluate the feasibility of the intra-operative application of a specimen PET/CT imager in a clinical setting. Materials and methods: this is a pilot analysis performed in three patients who received an intra-operative administration of (68)Ga-PSMA-11 (n = 2) and (68)Ga-DOTA-TOC (n = 1), respectively. Patients were administrated with PET radiopharmaceuticals to perform radio-guided surgery with a beta-probe detector during radical prostatectomy for prostate cancer (PCa) and salvage lymphadenectomy for recurrent neuroendocrine tumor (NET) of the ileum, respectively. All procedures have been performed within two ongoing clinical trials in our Institute (NCT05596851 and NCT05448157). Pathologic assessment with immunohistochemistry (PSMA-staining and SSA immunoreactivity) was considered as standard of truth. Specimen images were compared with baseline PET/CT images and histopathological analysis. Results: Patients received 1 MBq/Kg of (68)Ga-PSMA-11 (PCa) or 1.2 MBq/Kg of (68)Ga-DOTA-TOC (NET) prior to surgery. Specimens were collected, positioned in the dedicated specimen container, and scanned to obtain high-resolution PET/CT images. In all cases, a perfect match was observed between the findings detected by the specimen imager and histopathology. Overall, the PET spatial resolution was sensibly higher for the specimen images compared to the baseline whole-body PET/CT images. Furthermore, the use of the PET/CT specimen imager did not significantly interfere with any procedures, and the overall length of the surgery was not affected using the PET/CT specimen imager. Finally, the radiation exposure of the operating theater staff was lower than 40 µSv per procedure (range 26–40 μSv). Conclusions: the image acquisition of specimens obtained by patients who received intra-surgery injections of (68)Ga-PSMA-11 and (68)Ga-DOTA-TOC was feasible and reliable also in a live-experience session and has been easily adapted to surgery daily practice. The high sensitivity, together with the evaluation of intra-lesion tumor heterogeneity, were the most relevant results since the data derived from specimen PET/CT imaging matched perfectly with the histopathological analysis. MDPI 2023-02-20 /pmc/articles/PMC9953571/ /pubmed/36831181 http://dx.doi.org/10.3390/biomedicines11020645 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Muraglia, Lorenzo
Mattana, Francesco
Travaini, Laura Lavinia
Musi, Gennaro
Bertani, Emilio
Renne, Giuseppe
Pisa, Eleonora
Ferrari, Mahila Esmeralda
Fumagalli Romario, Uberto
De Cobelli, Ottavio
Fusco, Nicola
Ceci, Francesco
First Live-Experience Session with PET/CT Specimen Imager: A Pilot Analysis in Prostate Cancer and Neuroendocrine Tumor
title First Live-Experience Session with PET/CT Specimen Imager: A Pilot Analysis in Prostate Cancer and Neuroendocrine Tumor
title_full First Live-Experience Session with PET/CT Specimen Imager: A Pilot Analysis in Prostate Cancer and Neuroendocrine Tumor
title_fullStr First Live-Experience Session with PET/CT Specimen Imager: A Pilot Analysis in Prostate Cancer and Neuroendocrine Tumor
title_full_unstemmed First Live-Experience Session with PET/CT Specimen Imager: A Pilot Analysis in Prostate Cancer and Neuroendocrine Tumor
title_short First Live-Experience Session with PET/CT Specimen Imager: A Pilot Analysis in Prostate Cancer and Neuroendocrine Tumor
title_sort first live-experience session with pet/ct specimen imager: a pilot analysis in prostate cancer and neuroendocrine tumor
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953571/
https://www.ncbi.nlm.nih.gov/pubmed/36831181
http://dx.doi.org/10.3390/biomedicines11020645
work_keys_str_mv AT muraglialorenzo firstliveexperiencesessionwithpetctspecimenimagerapilotanalysisinprostatecancerandneuroendocrinetumor
AT mattanafrancesco firstliveexperiencesessionwithpetctspecimenimagerapilotanalysisinprostatecancerandneuroendocrinetumor
AT travainilauralavinia firstliveexperiencesessionwithpetctspecimenimagerapilotanalysisinprostatecancerandneuroendocrinetumor
AT musigennaro firstliveexperiencesessionwithpetctspecimenimagerapilotanalysisinprostatecancerandneuroendocrinetumor
AT bertaniemilio firstliveexperiencesessionwithpetctspecimenimagerapilotanalysisinprostatecancerandneuroendocrinetumor
AT rennegiuseppe firstliveexperiencesessionwithpetctspecimenimagerapilotanalysisinprostatecancerandneuroendocrinetumor
AT pisaeleonora firstliveexperiencesessionwithpetctspecimenimagerapilotanalysisinprostatecancerandneuroendocrinetumor
AT ferrarimahilaesmeralda firstliveexperiencesessionwithpetctspecimenimagerapilotanalysisinprostatecancerandneuroendocrinetumor
AT fumagalliromariouberto firstliveexperiencesessionwithpetctspecimenimagerapilotanalysisinprostatecancerandneuroendocrinetumor
AT decobelliottavio firstliveexperiencesessionwithpetctspecimenimagerapilotanalysisinprostatecancerandneuroendocrinetumor
AT fusconicola firstliveexperiencesessionwithpetctspecimenimagerapilotanalysisinprostatecancerandneuroendocrinetumor
AT cecifrancesco firstliveexperiencesessionwithpetctspecimenimagerapilotanalysisinprostatecancerandneuroendocrinetumor